Evidence map›Paper›PMID 38022849›Full record

ArticleMolecular and clinical oncology2023

Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma.

Xiaolong Liu, Xin Li, Ling Wang, Kaihua Yu, Dean Wu, Pengxian Tao, Yulan Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiaolong LiuThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Xin LiThe General Surgery Department, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China.
Ling WangDepartment of Pathology, Lanzhou, Gansu 730000, P.R. China.
Kaihua YuThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Dean WuThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Pengxian TaoCadre Ward of General Surgery Department, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China.
Yulan LiThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Lanzhou University · CNGansu Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rho GTPASE-activating protein 23 (ARHGAP23) is known to activate RHO-GTPase and has an important role in the infiltration and metastasis of tumors. Although previous studies suggested its involvement in certain human cancers, its role in pan-cancer remains unclear. In the present study, the expression, prognosis and potential functions of ARHGAP23 in pan-cancer were evaluated through various public databases such as Human Protein Atlas, Tumor IMmune Estimation Resource, Gene Set Co-Expression Analysis, Gene Expression Profiling Interactive Analysis, cBio Cancer Genomics Portal, Tumor-Immune System Interactions Database (TISIDB) and others. Through these data combined with a variety of biological information analysis methods, the potential role of ARHGAP23 as a carcinogenic gene was explored in the present study. The present analysis revealed that ARHGAP23 expressed abnormalities in >10 tumors, which was associated with differences in prognosis. Furthermore, the findings of the present study indicated that ARHGAP23 is associated with DNA methylation and multiple immune cell infiltrations in these tumors. ARHGAP23 expression was related to clinical prognosis, DNA methylation and immune infiltration. These findings support the potential of ARHGAP23 as a prognostic biomarker and a molecular target for cancer treatment.

Indexed as

biomarkerpan-cancerpancreatic adenocarcinomaprognosisRho GTPASE-activating protein 23

Identifiers

PMID38022849
PMCPMC10666083
OpenAlexW4388297079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.